Nova Eye Medical (EYE) Discussion, page-599

No problem, I can't understand why this company is so undervalued either especially when AMD is arguably one of the costliest diseases (in $ terms). The market is huge and extremely lucrative and drugs for just 10% of the total patient population are generating 10s of billions of dollars each year (2RT can potentially treat 70% of total patients and at the moment their are no alternatives). I think the partnership arrangement will be key to helping the market understand the enormity of this opportunity, and based on the info posted above we should expect that partnership arrangement in a month or so.

Then there is the near term opportunity of iTrack Advance, which was recently FDA approved and every single sign points to this device being superior to existing options and therefore generating extremely high revenue growth in the high double to triple digits in FY24

Market is completely blind at the moment imo